Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator's product

12Citations
Citations of this article
72Readers
Mendeley users who have this article in their library.

Abstract

Background: Existence of anti-malarial generic drugs with low bioavailability marketed on sub-Saharan Africa raises a concern on patients achieving therapeutic concentrations after intake of such products. This work compared bioavailability of one generic tablet formulation with innovator's product. Both were fixed dose combination tablet formulations containing artemether and lumefantrine. Methodology. The study was conducted in Dar Es Salaam, Tanzania, in which a survey of the most abundant generic containing artemether-lumefantrine tablet formulation was carried out in retail pharmacies. The most widely available generic (Artefan®, Ajanta Pharma Ltd, Maharashtra, India) was sampled for bioavailability comparison with Coartem® (Novartis Pharma, Basel, Switzerland) - the innovator's product. A randomized, two-treatment cross-over study was conducted in 18 healthy Tanzanian black male volunteers. Each volunteer received Artefan® (test) and Coartem® (as reference) formulation separated by 42 days of drug-free washout period. Serial blood samples were collected up to 168 hours after oral administration of a single dose of each treatment. Quantitation of lumefantrine plasma levels was done using HPLC with UV detection. Bioequivalence of the two products was assessed in accordance with the US Food and Drug Authority (FDA) guidelines. Results: The most widely available generic in pharmacies was Artefan® from India. All eighteen enrolled volunteers completed the study and both test and reference tablet formulations were well tolerated. It was possible to quantify lumefantrine alone, therefore, the pharmacokinetic parameters reported herein are for lumefantrine. The geometric mean ratios for Cmax, AUC 0-t and AUC0-∞ were 84% in all cases and within FDA recommended bioequivalence limits of 80% - 125%, but the 90% confidence intervals were outside FDA recommended limits (CI 49-143%, 53 - 137%, 52 - 135% respectively). There were no statistical significant differences between the two formulations with regard to PK parameters (P > 0.05). Conclusions: Although the ratios of AUCs and Cmax were within the acceptable FDA range, bioequivalence between Artefan® and Coartem® tablet formulations was not demonstrated due to failure to comply with the FDA 90% confidence interval criteria. Based on the observed total drug exposure (AUCs), Artefan® is likely to produce a similar therapeutic response as Coartem®. © 2013 Minzi et al.; licensee BioMed Central Ltd.

Figures

  • Table 1 Volunteers demographic and baseline characteristics (n = 18)
  • Table 2 % Ratio of untransformed data (Artefan® to Coartem®) and a comparison of data obtained by Norvatis
  • Figure 1 Mean plasma concentration-time profiles of lumefantrine in 20/120 mg Coartem® or Artefan® (generic) tablet formulation. Error- B
  • Table 3 Confidence interval from log transformed data for Bioequivalence assessment
  • Figure 2 The 90% confidence interval for average bioequivalence measures (Cmax and AUC) plotted over the FDA bioequivalence criteria boundary (The red dotted lines represent the FDA recommended lower and upper limits of the 90% confidence interval for Test/Reference ratio).

References Powered by Scopus

2747Citations
1232Readers

Antimalarial drug resistance

932Citations
584Readers
Get full text
298Citations
78Readers
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Minzi, O. M. S., Marealle, I. A., Shekalaghe, S., Juma, O., Ngaimisi, E., Chemba, M., … Sasi, P. (2013). Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product. Malaria Journal, 12(1). https://doi.org/10.1186/1475-2875-12-174

Readers over time

‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘25036912

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 31

76%

Researcher 6

15%

Lecturer / Post doc 3

7%

Professor / Associate Prof. 1

2%

Readers' Discipline

Tooltip

Medicine and Dentistry 20

51%

Pharmacology, Toxicology and Pharmaceut... 11

28%

Nursing and Health Professions 4

10%

Agricultural and Biological Sciences 4

10%

Save time finding and organizing research with Mendeley

Sign up for free
0